Flexion Therapeutics (FLXN) Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA
Tweet Send to a Friend
Flexion Therapeutics, Inc. (Nasdaq: FLXN) announced today the enrollment of the first patient in a clinical trial to evaluate the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
